Adherence of Saudi women with epilepsy to folic acid intake in the preconceptional period in two tertiary care hospitals in Riyadh: A cross sectional study

Ali Alanazi a,b,c, Ahmed Alqahtani d, Mohammad Alfaehadi d, Saleh Alduhayan d, Abdulaziz Alfadhel d, Waleed Alharbi d, Raghad Alharthi d, Emad Masuadi e, Majed Alhammed f, Ahmad Abulaban a,b,c

a Division of Neurology, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia
b King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
c King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
d College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
e Research Unit, College of Medicine, King Saud Bin Abdulaziz University for Health Science, Riyadh, Saudi Arabia
f King Fahad Medical City Riyadh, Saudi Arabia

Article info
Article history:
Received 18 December 2021
Revised 27 February 2022
Accepted 2 March 2022
Available online 9 March 2022

Keywords:
Epilepsy
Women with epilepsy
Congenital anomalies
Folic acid
Adherence

Abstract
Antiseizure medication have been associated with an increasing risk of congenital anomalies. Medical authorities recommend taking folic acid during the pre-conceptional period to reduce the risk of congenital malformations in the newborns of women with epilepsy (WWE). In this cross-sectional study, we aimed to measure the adherence of Saudi WWE to folic acid intake. We included WWE visiting outpatient epilepsy clinics in King Abdulaziz Medical City and King Fahad Medical City in Riyadh between September 2017 and August 2018. By consecutive non-probability sampling, we identified 85 patients who met the inclusion criteria of the study. The data were collected by a self-administered questionnaire. We found that the mean age of the subjects was 33 ± 7.5 years. One third were university graduates. Eighty percent were aware of the role of folic acid in preventing congenital anomalies, and 63.9% were taking it during the preconceptional period. No association was found between educational level and adherence to folic acid intake. In conclusion, adherence to folic acid intake among Saudi WWE is not optimal. More efforts are needed to increase patient adherence to folic acid intake.

Introduction
Epilepsy is a disorder of the brain characterized by a long-lasting predisposition to generate epileptic seizures [1]. It is one of the most prevalent neurological diseases around the world. According to a meta-analysis of international studies, the prevalence of active epilepsy is 6.38 per 1000 people. Approximately 80% of people with epilepsy live in low- and middle-income countries [2,3]. In Saudi Arabia, the prevalence of epilepsy is 6.54 per 1000 people [4].

Epilepsy is a chronic disease, so patients with epilepsy rely most of their lives on drugs, especially anti-seizure medications (ASMs). Unfortunately, maternal exposure to ASM during pregnancy is associated with an increased risk of congenital anomalies and developmental disorders in the newborns [5]. The European Registry of Antiepileptic Drugs and Pregnancy (EURAP) indicates a risk of congenital anomalies ranging from 2% for lamotrigine at doses of less than 300 mg per day to 24% for valproate at doses of more than 1500 mg per day, establishing an association between higher ASM doses and the risk of congenital anomalies [6]. Locally, a study conducted in Saudi Arabia in 1999, representing 79 pregnancies in 44 Saudi women, showed a probability of 2.5% for a congenital malformation in Saudi women with epilepsy (WWE) using ASMs [7].

The occurrence of congenital anomalies in critical periods of organogenesis is associated with folic acid intake, as folic acid has a major role in preventing malformation and the well-being of the embryo. Inadequate folic acid intake during pregnancy is associated with intrauterine growth retardation, preterm abor- tions, and neural tube defects. Studies have shown that folic acid supplementation decreased the incidence of neural tube defects. In the other hand, some ASMs are associated with a reduction in folic acid; this is especially the case for barbiturates, phenytoin, and carbamazepine, which may cause a severe reduction of up to 90% in serum folate levels. Lamotrigine was developed initially as antifolate drug, although, this effect was not confirmed clinically.
Others, such as valproate, have no effect on serum levels but may affect folic acid metabolism by inhibiting metabolic enzymes [8–10]. The American Academy of Neurology (AAN) recommends folic acid supplementation in the pre-conceptional period to reduce the risk of major congenital malformations in the newborns of women with epilepsy who take ASMs [11].

Studies have shown suboptimal adherence of women with epilepsy to folic acid intake. One study conducted in China showed that 35.3% of pregnant women with epilepsy had never taken folic acid, and less than one-third of the study sample started taking folic acid before conception [12]. Another study conducted in Brazil showed an adherence rate of 42% for folate supplementation in WWE [13]. The Epilepsy Birth Control Registry (EBCR) indicated a prevalence of 46.7% for folic acid use among WWE [14]. In Saudi Arabia, several studies conducted in the general population showed poor pre-conceptional adherence to folic acid intake among Saudi women [15–17].

However, the adherence of Saudi WWE to folic acid intake is unknown. The aim of the present study was therefore to determine adherence of Saudi WWE to folic acid intake in the pre-conceptional period and to study the factors that could increase compliance with folic acid supplementation during the pre-conceptional period.

Methods

Study design, area, and settings

This cross-sectional study surveyed all female patients with epilepsy who visited outpatient epilepsy clinics between September 2017 and August 2018 in two different tertiary centers in Riyadh: King Abdulaziz Medical City - Riyadh (KAMC-R) and King Fahad Medical City (KFMC). The study was approved by the institutional review boards in both centers, and the consent form was used as the cover page of the questionnaire.

Identification of study participants

A consecutive non-probability sampling technique was used in the study to enroll all patients who met the inclusion criteria. The inclusion criteria of the study were Saudi women aged between 18–50 years who had been diagnosed with epilepsy by a neurologist and who had visited the epilepsy clinics in any of the study centers during the study period. Women who were not married prior to the study were excluded because out-of-wedlock births in Saudi Arabia are exceedingly rare due to religious, cultural and legal reasons.

Data collection process

The data were collected using a self-administered questionnaire from all patients who met the inclusion criteria. The questionnaire was developed in the English language by the research team and then translated by a certified translator to Arabic, followed by back-translation to English by another certified translator to ensure compatibility. The questionnaire was validated by three experts in the field of neurology to assess content validity. A pilot study was conducted using 24 subjects in the same study population to assess the reliability of the questionnaire and yielded a Cronbach’s alpha score of 0.8. The consent forms were given to the patients by the co-investigators, who collected the data when the patients came to a routine appointment in outpatient epilepsy clinics. The data collected in this study were based on selected sociodemographic and clinical factors and the patient’s folic acid supplementation status. Sociodemographic factors included maternal age, social status, education level, and occupational status. Independent variables for the enrolled patients included the duration of epilepsy, seizure frequencies, anti-seizure medication use, and number of pregnancies. A five-point Likert scale was used to assess the outcome variable of the patient’s adherence to folic acid during the pre-conceptional period.

Data analysis

Adherence of folic acid was estimated as the mean score of the nine items using a five-point frequency scale from never to always. A score of three or more was considered to indicate adherence to folic acid intake. Microsoft Excel 2016 was used for data entry, and IBM SPSS Statistics for Windows, Version 20.0, was used for data analysis. The categorical data, such as educational level and social status, were presented as frequencies and percentages, while numerical data, such as the number of pregnancies and age, were presented as mean and standard deviation (SD). The Chi-square test, or the Fisher exact test when appropriate, was used to assess the association of adherence (yes/no) with baseline characteristics such as educational level. A test was considered significant if the p-value was less than 0.05.

Results

Eighty-five women with epilepsy were studied. The age range was 18 to 50 years (mean ± SD, 33 ± 7.5). Fifty-eight (69.9%) patients lived outside Riyadh. Twenty-nine (34.1%) patients had a university degree, while 37 (43.5%) had a high school certificate as the last degree in education. Four women were pregnant for the first time during the study.

Seventy-two (84.7%) patients had been pregnant before; 57 (79.2%) of those patients had been on ASMs during their previous pregnancies. Of 72 patients who were pregnant, 50 (69.4%) had planned their pregnancies. Only 39 (45.9%) subjects reported that they had used at least one contraceptive method. There was no statistically significant correlation between the folic acid intake and use of contraception. Sixty-seven (78.8%) of the subjects had borne at least one child, and a total of 190 children were borne by them. Only 1 child (0.5%) had a congenital anomaly in the form of a cleft palate. The duration of epilepsy among the subjects was 10 ± 6.5 years. Sixty-eight (80.0%) patients experienced more than 3 seizures in their lifetime [Table 1].

Seventy-nine (92.9%) subjects had heard about folic acid, and 68 (80.0%) were aware of the importance of folic acid in preventing congenital anomalies. Sixty-eight (80%) subjects were aware that women with epilepsy needed more folic acid than was required

| Table 1 | Sociodemographic and Clinical Variables. |
|---------|-----------------------------------------|
| Social Status | N | % |
| Married | 78 | 91.80% |
| Divorced | 5 | 05.90% |
| Widowed | 2 | 02.40% |
| Occupational Status* | N | % |
| Unemployed | 67 | 79.80% |
| Employed | 17 | 20.20% |
| Number of Antiseizure Medications | N | % |
| None | 2 | 02.40% |
| Monotherapy | 52 | 61.20% |
| Polytherapy | 31 | 36.50% |
| Number of Seizure in lifetime | N | % |
| One to Three | 17 | 20.00% |
| More than Three | 68 | 80.00% |
| Dosage of Folic Acid | N | % |
| 1 mg | 11 | 12.94% |
| 5 mg | 40 | 47.05% |
| Dosage Unknown | 34 | 40.00% |

* Missing one value.
Folic Acid Supplementation.

by the general population. Only 46 (56.1%) of all the subjects were taking folic acid at the time of the study [Table 2].

A total of 76 women were pregnant before or during the study. Fifty-nine (77.6%) of them were adherent to a folic acid intake. Only 46 (63.9%) were taking folic acid for the three months before pregnancy. Table 3 shows the association between the sociodemographic variables, including age, social status, educational level, and occupational status, and adherence to folic acid intake.

Discussion

Approximately two-thirds of Saudi WWE were adherent to folic acid intake in the preconceptional period, and more than three-quarters of them were generally adherent to folic acid by contrast. In previous studies, the adherence rate for folic acid intake in the preconceptional period among women in Saudi Arabia ranged from 4 to 22% [15–17]. Also, another study done in Qatar and Oman showed low adherence rate to folic acid in the preconceptional period [18]. This disparity in the results between our study and previous studies in the same country possibly reflects a greater concern among women with epilepsy regarding congenital anomalies that are linked to ASMs and therefore a greater motivation for compliance with folic acid intake. However, the adherence rate in our cohort was also higher than the reported rate in international studies done in China (29.1%) and Brazil (42.4%) among WWE [12,13]. Because the sample came from tertiary medical centers and the subjects were followed in specialized epilepsy clinics, sampling bias might have contributed to this relatively high adherence rate.

Most of our study subjects (80%) were aware of the role of folic acid in preventing congenital anomalies, and this result is comparable to results of a recent study done in 2018 among Saudi women [19]. Nevertheless, the awareness of Saudi WWE regarding the role of folic acid was higher in our cohort than in Saudi women studied in 2012 and 2013 [15,20]. This difference could indicate an increased awareness in the last few years among Saudi women, or it may simply be due to random variation between studies conducted at different centers. However, physicians played an important role as a source of information about folic acid, as more than 90% of the subjects in our study heard about folic acid from their physicians. A similar finding was noted in another local study and suggests that the time allocated for patient education during clinical visits is an important factor for increasing awareness [19].

We found no association between educational level and adherence to folic acid intake. By contrast, previous studies done in Brazil and China showed evidence of an association between educational level and adherence to folic acid. The absence of an association in our study is possibly due to its small sample size, and the important educational role played by the physicians might have offset the education level effect.

The use of ASMs has a risk of causing congenital anomalies. In this study, we found only one child (0.5%) with a congenital anomaly that could be attributed to ASM, and this frequency was lower than expected, based on previous local and international studies [7,21]. This apparently low incidence of congenital anomalies can be attributed to two factors: the selection bias of the study sample and the fact that more than 20% of the subjects had not been on ASM in their previous pregnancies.

In addition to the intrinsic shortcomings of survey research, our study has several other limitations. The participants were selected from a convenience sample, which could introduce a selective bias. Likewise, our sampling frame may not represent the target population, as we took the sample from two tertiary centers from the capital city, where the social and economic status of its inhabitants are expected to differ from other regions. The study is also underpowered because of its small sample size in terms of finding a significant association between adherence to folic acid intake and demographic factors.

In conclusion, this study showed suboptimal adherence to folic acid intake and awareness of its significance among Saudi WWE. Establishing a national registry of antiseizure medications and pregnancy or participation by national medical centers in an international established registry will help in conducting high-quality prospective observational studies that will avoid the shortcomings of small underpowered studies.

Ethical statement

The study was approved by the institutional review boards in King Abdullah International Medical Research Center and King Fahad Medical cit and the consent form was used as the cover page of the questionnaire.

Table 2

Folic Acid Supplementation.

| Know about Folic Acid from: | N  | %   |
|----------------------------|----|-----|
| Media                      | 11 | 13.40% |
| Relatives                  | 20 | 24.40% |
| Physician                  | 75 | 91.50% |
| Neurologist                | 46 | 56.10% |
| OBGYN                      | 52 | 63.40% |
| Family Physician           | 2  | 02.40% |
| Pharmacist                 | 1  | 01.20% |
| Never Prescribed           | 2  | 02.40% |

| Prescribed Folic Acid by: | N  | %   |
|--------------------------|----|-----|
| Neurologist              | 46 | 56.10% |
| Family Physician         | 2  | 02.40% |
| Pharmacist               | 1  | 01.20% |
| Never Prescribed         | 2  | 02.40% |

* Patient can select more than one option.

Table 3

Association of the Adherence to Folic Acid Intake in the preconceptional period and Sociodemographic Variable.

| Age*                  | Not adherent to folic acid intake | N = 17 | %   | Adherent to folic acid intake | N = 59 | %   |
|-----------------------|-----------------------------------|--------|-----|-------------------------------|--------|-----|
| Less than 30 years    | 3                                 | 13.6%  | 19  | 86.4%  | 0.37 |
| Between 30 and 39 years | 6                              | 18.2%  | 27  | 81.8%  | 0.41 |
| More than 39 years    | 4                                 | 33.3%  | 8   | 66.7%  | 0.04 |
| Social Status         |                                   |        |     |                                |        |     |
| Married               | 15                                | 21.1%  | 56  | 78.9%  | 0.33 |
| Unmarried             | 2                                 | 40.0%  | 3   | 60.0%  | 0.76 |
| Education Level       |                                   |        |     |                                |        |     |
| Less than High School | 4                                 | 22.2%  | 14  | 77.8%  | 0.76 |
| High School           | 6                                 | 18.8%  | 26  | 81.2%  | 0.66 |
| University            | 7                                 | 26.9%  | 19  | 73.1%  | 0.66 |
| Occupational Status*  |                                   |        |     |                                |        |     |
| Unemployed            | 15                                | 24.6%  | 46  | 75.4%  | 0.41 |
| Employed              | 2                                 | 14.3%  | 12  | 85.7%  | 0.41 |

* Variables with some missing values.
Conflict of interest

We have no conflict of interest.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia 2014;55(4):475–82.

[2] Epilepsy. https://www.who.int/en/news-room/fact-sheets/detail/epilepsy#. Accessed August 15, 2021.

[3] Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon C-S, Dykeman J, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Kirlstein. Neurology 2017;88(3):296–303.

[4] Al Rajeh S, Awada A, Bademosi O, Ogunniyi A. The prevalence of epilepsy and other seizure disorders in an Arab population: A community-based study. Seizure 2001;10(6):410–4. https://doi.org/10.1016/S1059-1311(01)0024-1.

[5] Kluger BM, Meador KJ. Teratogenicity of antiepileptic medications. Semin Neurol 2008;28(3):328–35. https://doi.org/10.1055/s-2008-1079337.

[6] Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10(7):609–17.

[7] Al BM, Al-Othman A. Outcome of pregnancies in epileptic women: A study in Saudi Arabia. Seizure 1999;8(1):26–9. https://doi.org/10.1053/seiz.1998.0239.

[8] Morrell MJ. Folic acid and epilepsy. Epilepsy Curr 2002;2(2):31–4. https://doi.org/10.1046/j.1535-7597.2002.00017.x.

[9] Yovvanathan M, Tremblay KA, Kish-Doto J, Middleton JC, Coker-Schwimmer EJL, Nicholson WK. Folic acid supplementation for the prevention of neural tube defects in an evidence-based study. JAMA - J Am Med Assoc 2017;317(2):190–203. https://doi.org/10.1001/jama.2016.19182.

[10] Sander JWS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsia 1992;33(1):89–92. https://doi.org/10.1111/j.1528-1167.1992.tb00114.x.

[11] Harder MD CL, Pennell MD PB, Koppel MD BS, et al. Practice Parameter update: Management issues for women with epilepsy – Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment. Neurology 2009;73(2):142–149. http://www.neurology.org/content/73/2/142.abstract.

[12] Hao N, Xia W, Tang Y, Wu M, Jiang H, Lin X, et al. Periconceptional folic acid supplementation among pregnant women with epilepsy in a developing country: A retrospective survey in China. Epilepsy Behav 2015;44:27–34.

[13] Passarelli V, de Figueiredo NSV, Moraes Angst DB, Baldocchi MA, Guimarães Rocha MS. Folate use in women with epilepsy: Predictors of adherence in a specialized tertiary outpatient. Epilepsy Behav 2015;43:74–8. https://doi.org/10.1016/j.yebeh.2014.12.006.

[14] Herzog AG, MacEachern DB, Mandle HB, Cahill KE, Fowler KM, Davis AR, et al. Folic acid use by women with epilepsy: findings of the epilepsy birth control registry. Epilepsy Behav 2017;72:156–60.

[15] Al-Akhfash AA, Abdulla AM, Abdulgafar JI, Almesned AA. Maternal knowledge and use of folic acid among Saudi females. Saudi Med J 2013;34(11):1173–8.

[16] Al Rakaf MS, Kurdi AM, Ammari AN, Al Hashem AM, Garne E, et al. Patterns of folic acid use in pregnant Saudi women and prevalence of neural tube defects – Results from a nested case-control study. Prev Med Reports 2015;2:572–6.

[17] McWalter P, Al Shmassi A, Eldali A. Awareness and use of folic acid in a clinic-based Saudi pregnant population. Saudi Med J Sci 2015;3(2):141. https://doi.org/10.4103/1658-631x.156425.

[18] Al-Akhfash AA, Al-Khasaei AA. Knowledge and use of folic acid among pregnant Arabian women residing in Qatar and Oman. Int J Food Sci Nutr 2008;59(1):70–9. https://doi.org/10.1080/09637480701688770.

[19] Al-Mousa E, Al-Mousa H. Awareness of folic acid use among Saudi women attending outpatient clinics at King Fahd Medical City, J Fam Med Prim Care 2017;7:5(5):957–62. https://doi.org/10.4103/jfpmc.jfpmc_174_18.

[20] Al-Hakeem M. Impact of education on knowledge and use of folic acid among Saudi Women. Pakistan J Med Sci 2012;28(4):686–90. https://doi.org/10.4103/0300-2203.128420.

[21] Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Pennell MD et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018;17(6):530–8.